Question 1

Has Catherine Small, MD received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $2,686,651 in general payments to Catherine Small, MD across 322 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Catherine Small, MD did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Catherine Small, MD come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Gilead	25	$1,137,033
Merck	250	$1,103,715
Karyopharm Therapeutics Inc.	22	$166,683
Shire North American Group Inc	9	$126,747
Takeda Pharmaceuticals U.S.A., Inc.	10	$48,458
GSK	2	$45,343
Janssen Research & Development, LLC	2	$41,135
Ablynx NV	1	$16,180
Partner Therapeutics, Inc.	1	$1,357

Catherine Small, MD

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Other infectious disease in Valhalla